Clinical Research Services
Autoimmune disease drug clinical research services encompass a comprehensive suite of specialized support solutions designed to facilitate the planning, execution, and completion of clinical trials for autoimmune disease therapies. Protheragen's autoimmune disease drug clinical research services are distinguished by a set of core features designed to address the unique challenges of this field and deliver exceptional value to sponsors and researchers.
Overview of Autoimmune Disease Drug Clinical Research
Autoimmune disease drug clinical research is a specialized branch of clinical research focused on evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of therapeutic agents designed to treat autoimmune disorders—chronic conditions characterized by the immune system's aberrant attack on the body's own tissues and organs. Unlike general clinical research, this subset addresses the unique complexities of autoimmune diseases, which encompass over 80 distinct conditions, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), psoriasis, and systemic sclerosis (SSc). The core scientific premise of this research lies in understanding the disrupted immune regulatory mechanisms that drive these diseases, such as the overproduction of autoantibodies, dysregulation of cytokine pathways, and abnormal activation of T and B cells, and using this knowledge to validate therapies that restore immune homeostasis.
Fig.1 Investigator Initiated Trial workflow within BISR. (Mudaranthakam D. P., et al., 2020)
These research studies follow a rigorous, phase-based framework established by global regulatory bodies, including the FDA, EMA, and NMPA, to ensure the reliability and translatability of results. Phase I trials typically enroll 20-100 healthy volunteers or patients to assess safety, tolerability, and optimal dosage ranges; Phase II trials expand to 100-300 patients to preliminary validate efficacy and further characterize safety profiles; Phase III trials involve 300-3,000+ patients across multiple centers to confirm efficacy, monitor long-term safety, and compare the new therapy to standard-of-care treatments; and Phase IV trials conduct post-marketing surveillance to identify rare adverse events and evaluate real-world effectiveness in diverse patient populations.
Key Methodologies in Autoimmune Disease Drug Clinical Research
Autoimmune disease drug clinical research uses both objective and subjective outcome measures to fully capture the complex nature of chronic autoimmune disorders. Objective assessments include laboratory tests, autoantibody analysis, cytokine detection, and imaging studies, while subjective measures cover patient-reported pain, fatigue, and quality of life. This combined method is essential because symptoms vary widely even among patients with the same diagnosis, and treatment effects may differ between objective markers and patient experience. Additionally, clinical trials in this field rely on control groups, randomization, and single or double blinding to reduce bias and ensure reliability. These designs help isolate the real effects of the study drug by eliminating external influences, ensuring that observed improvements in disease activity can be reliably attributed to the treatment being tested.
Our Services
Protheragen offers end-to-end autoimmune disease drug clinical research services, tailored to the unique needs of each trial and designed to streamline the research process while maintaining the highest scientific standards. We leverage specialized expertise in autoimmune disease pathophysiology, clinical trial design, and data management to address the specific challenges of this field, ensuring that trials are efficient, reliable, and positioned for success.
One-stop Solution for Clinical Research
Protocol Design & Feasibility Analysis
Protheragen provides professional protocol design support for investigator-initiated trials, combining the characteristics of different disease research directions to formulate scientifically rigorous and operable trial protocols, including the setting of inclusion and exclusion criteria, the selection of outcome indicators and the formulation of trial procedures. At the same time, a comprehensive feasibility evaluation is conducted for the designed protocol, focusing on analyzing the rationality of subject recruitment plans, the matching degree of research technical requirements and existing conditions, and the scientificity of sample size setting, to lay a solid foundation for the smooth implementation of IIT projects.
Disease Area Customized Support
Protheragen provides targeted IIT research support for different disease areas, combining professional research experience in various therapeutic fields to formulate personalized trial implementation plans for investigators. For each specific disease area, the team can provide professional guidance on the selection of disease-specific efficacy and safety indicators, the design of trial follow-up plans, and the matching of research technical means, ensuring that the IIT project is highly adapted to the research characteristics of the corresponding disease field.
Data Management & Quality Control
Protheragen can build a complete data management system for IIT projects, including the development and deployment of electronic data capture (EDC) systems suitable for the characteristics of investigator-initiated trials, to realize real-time collection, storage and traceability of trial data. Professional data quality control services are provided, with multiple rounds of data verification, discrepancy resolution and data cleaning carried out in accordance with GCP guidelines, to ensure the accuracy, completeness and consistency of trial data, and to avoid data errors affecting the research results.
Statistical Analysis & Result Interpretation
The company is equipped with professional biostatisticians who can provide targeted statistical analysis solutions for IIT projects, including the selection of appropriate statistical methods, sample size calculation, and statistical analysis of trial data such as efficacy and safety indicators. In addition, in-depth interpretation of statistical analysis results is provided, combining clinical professional knowledge to explain the clinical significance behind the data results, and to sort out the logical relationship between data and research hypotheses, providing a reliable basis for the conclusion of the trial.
Scientific Reporting & Academic Dissemination
Protheragen can assist in the writing of various scientific reports for IIT projects, including trial summary reports, research papers and academic conference abstracts, and strictly follow the academic norms and writing requirements of the corresponding fields to ensure the standardization and academicity of the reports. At the same time, it provides professional support for the academic dissemination of IIT research results, including the selection of appropriate journals and conferences, the revision of manuscripts according to the review opinions, and the guidance of the submission process, to help investigators disseminate research results to the academic community.
- Industry Sponsored Trial (IST) Services
By Workflow
| Clinical Trial Phase | Description |
|---|---|
| Phase I Clinical Trial | Protheragen provides tailored protocol design and data analysis support for Phase I clinical trials, focusing on evaluating the safety, tolerability and optimal dosage range of the research drug in healthy volunteers or small-scale patient groups. |
| Phase II Clinical Trial | Protheragen offers specialized trial design and efficacy verification services for Phase II clinical trials, expanding the research population to preliminary confirm the drug's therapeutic effect on the target disease and further characterize its safety profile. |
| Phase III Clinical Trial | Protheragen provides full-process support for large-scale multi-center Phase III clinical trials, through expanded sample size to comprehensively confirm the drug's efficacy and long-term safety, and compare it with the standard of care to provide sufficient evidence for regulatory approval. |
| Phase IV Clinical Trial | Protheragen can deliver professional post-marketing surveillance and data analysis services for Phase IV clinical trials, monitoring the drug's real-world application effect and rare adverse events, and supplementing the drug's safety and efficacy information for the whole life cycle management. |
By Management
Project Team Allocation & Responsibility Definition
The company can configure a dedicated, multi-disciplinary professional project team for each IST project and clearly define the responsibilities of each team member to ensure efficient and orderly promotion of all trial links.
Trial Timeline Formulation & Milestone Supervision
The company can formulate a detailed and scientific trial implementation timeline for IST projects, set clear milestone nodes, and conduct real-time supervision and dynamic adjustment to ensure the trial is completed on schedule.
Budget Planning & Cost Control
The company can provide professional budget planning services for IST projects based on trial scale and research needs, and implement strict whole-process cost control to ensure the trial is completed within the planned budget with optimal cost performance.
Multi-Center Coordination & Standardization Unification
The company can realize efficient communication and coordination among all research centers of IST projects, and unify trial operation standards and evaluation criteria to ensure the consistency and standardization of trial implementation across all centers.
Data Integrity Supervision & Quality Audit
The company can build a full-process data integrity supervision system for IST projects, conduct regular data quality audits and spot checks, and eliminate data errors to ensure the authenticity and traceability of all trial data.
Adverse Event Monitoring & Risk Assessment
The company can carry out real-time and comprehensive monitoring of adverse events in IST projects, conduct professional risk assessment on the correlation between adverse events and research drugs, and timely initiate risk control measures if necessary.
Document Standardization Compilation & Archiving
The company can provide standardized document compilation services for all trial-related documents of IST projects, and implement systematic and standardized archiving management to meet the regulatory requirements of document traceability and inspection.
Sponsor Communication & Progress Reporting
The company can establish a regular and efficient communication mechanism with sponsors for IST projects, conduct timely and detailed progress reporting, and feedback trial problems and solutions to ensure sponsors' real-time grasp of project status.
Regulatory Guideline Compliance & Dynamic Adaptation
The company can track the latest updates of global regulatory guidelines in real time, ensure that the whole implementation process of IST projects is fully compliant with relevant guidelines, and make dynamic adjustments to trial plans according to guideline changes.
Trial Resource Allocation & Optimization Adjustment
The company can reasonably allocate human, material and technical resources for IST projects according to the trial progress and actual needs, and conduct real-time optimization and adjustment to improve the overall operation efficiency of the trial.
Disease Areas of Focus
With specialized knowledge in autoimmune disease pathways, Protheragen delivers modality-specific clinical research strategies for small molecules, therapeutic antibodies, probiotic, and advanced therapies including cell and gene-based interventions. We bridge discovery and development through bespoke preclinical research, de-risking your program from concept to clinic. Contact us today to discuss how our integrated solutions can advance your specific development needs.
Reference
- Mudaranthakam, Dinesh Pal, et al. "Improving the efficiency of clinical trials by standardizing processes for investigator initiated trials." Contemporary clinical trials communications 18 (2020): 100579.